- Home
- STSS vs LUNG Comparison
STSS vs LUNG Comparison
Compare STSS & LUNG Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | STSS | LUNG |
|---|---|---|
| Founded | 2017 | 1995 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Industrial Specialties |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 68.7M | 72.2M |
| IPO Year | 2022 | 2020 |
Fundamental Metrics
Financial Performance| Metric | STSS | LUNG |
|---|---|---|
| Price | $1.43 | $1.46 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 7 |
| Target Price | N/A | ★ $6.81 |
| AVG Volume (30 Days) | ★ 1.2M | 343.2K |
| Earning Date | 03-26-2026 | 02-18-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | $306,344.00 | ★ $91,664,000.00 |
| Revenue This Year | N/A | $9.21 |
| Revenue Next Year | N/A | $5.03 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | ★ 15.59 |
| 52 Week Low | $1.42 | $1.31 |
| 52 Week High | $211.20 | $9.37 |
Technical Indicators
Market Signals| Indicator | STSS | LUNG |
|---|---|---|
| Relative Strength Index (RSI) | 30.81 | 26.73 |
| Support Level | $2.08 | $1.68 |
| Resistance Level | $2.32 | $1.92 |
| Average True Range (ATR) | 0.19 | 0.10 |
| MACD | -0.05 | -0.03 |
| Stochastic Oscillator | 2.58 | 3.88 |
Price Performance
Historical ComparisonAbout STSS Sharps Technology Inc.
Sharps Technology Inc is a medical device company. It offers syringes and other safety products. Sharps provensa, Securgard, and Sologard are ultra-low waste smart safety syringes designed to eliminate potentially infectious and accidental needlestick injuries.
About LUNG Pulmonx Corporation
Pulmonx Corp is a commercial-stage medical technology company. It provides a minimally invasive treatment for patients with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). The company's solutions are comprised of the Zephyr Endobronchial Valve, the Chartis Pulmonary Assessment System and the StratX Lung Analysis Platform. It generates revenue through the sale of products to distributors and hospitals in the United States which a key revenue generating market, Europe, Middle-East and Africa, Asia Pacific and other regions.